Results From 10-Patient Case Study Lead to Phase III Clinical Trial for Patients with Duchenne Muscular Dystrophy
Cedars-Sinai Heart Institute researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with
Duchenne muscular dystrophy, a genetic muscle-wasting disease that rarely is seen in girls but affects one in 3,500 male babies, profoundly shortening life expectancy. It is the most common fatal disease that affects children.
Muscle weakness begins in early childhood, often causing deformity of the arms, legs and spine. Heart and respiratory muscles often begin to fail before children reach early teen years. Although steroid medications – which often are not well tolerated – and other therapies may ease symptoms and delay the most severe effects, no disease-specific treatment exists, and patients rarely survive into their 30s.
But in this case study of 10 boys with Duchenne muscular dystrophy, also called DMD, a single dose of a drug often prescribed for erectile dysfunction or pulmonary hypertension corrected defective blood vessel mechanisms and restored blood flow to exercising muscles.
“The effects were immediate and dramatic, raising the question: If a single dose restores blood flow to muscle while the drug is in the patient’s system, could ongoing tadalafil administration provide sustained benefits, possibly preserve muscle and slow disease progression? If so, this would offer a new therapeutic strategy for DMD, and we have launched a randomized Phase III clinical trial to find out,” said Ronald Victor, MD, director of the Cedars-Sinai Center for Hypertension, associate director of clinical research at the Heart Institute and the Burns and Allen Chair in Cardiology Research. He is the senior author of a highlighted article in the May 7 online edition of Neurology.
Duchenne muscular dystrophy results from a genetic defect that eliminates a protein called dystrophin in the membranes of muscle cells. For more than 25 years, Victor has studied DMD and a less aggressive but debilitating variant called Becker muscular dystrophy. This form of muscular dystrophy, usually diagnosed in early adulthood, is caused by a reduction, but not absence, of dystrophin.
Victor led a research team that in 2000 discovered that the blood flow abnormality in the muscles of children with DMD was caused by a loss of nitric oxide, a signaling chemical that normally tells blood vessels to relax during exercise, increasing blood flow and oxygenation.
In studies of mice bred to represent diseases of dystrophin deficiency, the researchers found that drugs prescribed for other disorders of blood vessel function could restore muscle blood flow and enable the animals to exercise more, with less muscle injury. Tadalafil, known by the brand names Cialis and Adcirca, and sildenafil, called Viagra and Revatio, have long been approved by the Food and Drug Administration to treat erectile dysfunction and pulmonary hypertension, a serious illness that restricts blood flow to the lungs.
Translating these findings to a human clinical trial, Victor and his colleagues published in 2012 a study showing that tadalafil fully restored blood flow in eight of nine patients with Becker muscular dystrophy.
In the new study, investigators found that when boys with Duchenne muscular dystrophy performed handgrip exercises, the major artery of the arm and the blood vessels in muscles of the forearm failed to respond the way they did in healthy boys of similar ages, 8 to 13. But when the boys with DMD were given a single dose of tadalafil, normal vessel function and blood flow were restored. Similar results occurred when sildenafil, a drug with a similar mechanism of action on vessels but a different chemical structure, was used in place of tadalafil.
“Steroids and cardiac-protective blood pressure medication are increasingly prescribed at early ages for patients with Duchenne muscular dystrophy in an effort to delay by a few years the most devastating effects of the disease. But these treatments have no effect on the blood vessel dysfunction that prevents muscles from getting the oxygen they need,” said Victor. “In contrast, in our study, a single dose of tadalafil or sildenafil had an immediate effect. These are well-studied, well-tolerated drugs that are already on the market. If additional study confirms their benefits, repurposing the drugs for muscular dystrophy patients could quickly transform clinical practice.”
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Italfarmaco Provides Update on Ongoing Clinical Programs with Givinostat in Oral Presentation at XVIII International Conference on Duchenne and Beckeron February 22, 2021 at 12:12 pm
Analyses of long-term study with Givinostat in Duchenne Muscular Dystrophy boys continue to show delayed disease progression ---- EPYDIS Phase 3 pivotal clinical trial continues as planned with ...
- New drug molecules hold promise for treating fatal child diseaseon February 22, 2021 at 12:01 pm
Scientists have identified a way to "rescue" muscle cells that have genetically mutated, paving the way to a possible new treatment for rare childhood illness such as Duchenne Muscular Dystrophy (DMD) ...
- Glimmer of hope for generations of boys born with muscle wasting diseaseon February 18, 2021 at 7:33 am
New research gives hope medics might eventually be able to earlier diagnose and better treat a devastating and lethal muscle wasting disease.
- Duchenne UK and Parent Project Muscular Dystrophy Award $350,000 to Address Immunological Challenges of Gene Therapy in Duchenne Muscular Dystrophyon February 18, 2021 at 7:00 am
Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), ...
- Duchenne muscular dystrophyon February 18, 2021 at 12:59 am
Duchenne muscular dystrophy is an X-linked progressive, muscle-wasting disease that manifests in childhood as difficulties with movement. This Primer by Aartsma-Rus and colleagues discusses the ...
- Solid Biosciences to Present at Upcoming Investor Conferenceson February 17, 2021 at 4:47 am
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief ...
- Caring for Patients With Duchenne Muscular Dystrophy During COVID-19 Pandemicon February 16, 2021 at 11:59 am
Shifts in care prompted concerns regarding the effects of treatment lags for patients with Duchenne muscular dystrophy during the COVID-19 Pandemic.
- Virtual Reality Technologies Improve Outcomes in Duchenne Muscular Dystrophyon February 16, 2021 at 10:09 am
Virtual reality technologies may improve treatment outcomes in DMD and may be valuable in rehabilitation for patients.
- Global Duchenne Muscular Dystrophy Therapeutics Market 2020 Segmentation Analysis, Key Players, Industry Share and Forecast by 2025on February 9, 2021 at 5:46 pm
MarketsandResearch.biz is aimed at offering market research study on Global Duchenne Muscular Dystrophy Therapeutics Market 2020 by Company, Type and Application, Forecast to 2025, provides an ...
- Parent Project Muscular Dystrophy Receives $100,000 Award from Duchenne Research Fund to Address Neurobehavioral Issues in Duchenneon February 9, 2021 at 7:00 am
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today announced sponsorship from the Duchenne ...
via Bing News